Max Healthcare Institute Ltd Q4 FY2023 Concall Summary

Key Takeaways

• Free cash flow milestone achieved: ₹1,281 crore of free cash flow from ₹1,636 crore EBITDA, an ~80% conversion rate that management says answers the sector's historical critique of being a cash-flow mirage.
• Brownfield expansion proves immediately accretive: The 92-bed oncology block at Max Shalimar Bagh turned EBITDA positive in its first month (March), delivering a 35–40% EBITDA margin on incremental revenue.
• ARPOB growth levers are structural, not cyclical: Payor mix distillation (PSU share down to 29% from 40%+ in FY19), specialty mix improvement, and international patient revenue (now 120% of pre-COVID levels) all pushed ARPOB higher, with management seeing no reason for the climb to stop.
• PSU tariff revision adds a tailwind: A ~70% upward revision on four line items covering 10–12% of revenue translates to a ~4–5% overall billing increase to PSUs, with a further round expected in July for the remaining items.
• What to watch next quarter: Whether the Dwarka 300-bed project commissions by end of Q2 FY24 as guided, the July PSU tariff revision on diagnostics and packages, and any announcements on the promised asset-light growth model.

Free Cash Flow & Capital Allocation

• 80% EBITDA-to-FCF conversion: The ₹1,281 crore free cash flow print was positioned as the definitive rebuttal to the critique that Indian hospitals consume all their cash in capex.
• Self-funded expansion: The entire 2,900-bed network cost ₹4,500 crore, which management expects will be less than 50% of free cash flows over the next 4–5 years on a debt-free balance sheet, implying no need to raise capital.
• Maiden dividend declared: Despite what management calls a decadal investment opportunity, the company declared its first dividend, signaling confidence in the cash flow profile.
• M&A underwriting advantage: Management claims its EBITDA per bed is 50–55% higher than the industry average, giving it an underwriting edge: a PE fund must underwrite the industry case, while Max can underwrite its own superior unit economics and target a 20% ROCE three to five years out.

Abhay Soi: "The biggest critique of this sector was that the Indian Healthcare sector is a great investment but it is a mirage because there are no free cash flows. How do you invest? You have to keep raising money and keep reinvesting. We have Rs. 1,281 crore free cash flows coming with Rs. 1,636 crore EBITDA. That is almost 80% throughput of the free cash flows."

Brownfield Execution & Capacity Expansion

• Shalimar Bagh oncology block: The 92-bed addition commissioned 1 March was EBITDA positive in month one, with 35–40% margins on incremental revenue. Oncology patients from the pre-existing facility moved into the new block, freeing up the old block for lower-ARPOB business to climb up, so the new block was evaluated against the low-ARPOB baseline, not the high-ARPOB one.
• Dwarka 300-bed project: Interior work in progress, lifts under installation, medical equipment ordered; commissioning expected by end of Q2 FY24, subject to the developer obtaining an occupation certificate.
• Nanavati 329-bed project: Foundation and column work begun with L&T as contractor; commissioning expected by end of FY25.
• Sector 56 Gurgaon 300-bed Phase I: D-wall work complete, excavation underway; civil contractor mobilizing for a construction start by end of June.
• Max Smart / Vikrant site: Fast-tracking construction at the Vikrant site due to tree transplantation delays at Max Smart; in-principle environmental clearance received, with other approvals expected in the next 6–8 weeks.
• Max Vaishali expansion: An Agreement to Sell has been signed for adjacent land; the facility already operates above 80% occupancy, and the deal could unlock ~100 additional brownfield beds if consummated.
• Internal capacity unlocking: Management identified ~100 beds (3% of capacity) that can be unlocked internally, plus a couple of percentage points through occupancy elasticity, yielding ~4–5% volume growth before any new builds come online.

Abhay Soi: "EBITDA positive in the first month and giving a 35% to 40% EBITDA margin on the incremental revenue. This is something that we have always spoken about - Brownfields do not suppress your EBITDA, in fact, they are accretive."

ARPOB Drivers & Payor Mix

• Payor mix distillation: PSU share fell to 29% from 33% YoY and from 40%+ in FY19. As occupancy rises, the mix naturally distills toward cash, insurance, and international patients, and some hospitals are already doing ₹90,000+ ARPOB.
• PSU tariff revision mechanics: A ~70% upward revision on four line items (room rent for ICU beds, single room, IP consults, OP consults) covering 10–12% of revenue yields a ~4–5% overall billing increase to PSUs. Diagnostics, packages, and blood bank tariffs were not yet touched; another round is expected in July.
• PSU breakeven math shifts: The price hike raises the number of PSU beds that must be filled to offset switching off 100 PSU beds, from 40 to 55 and eventually to 70–80, making the switch marginal but still directionally accretive. At 80–85% occupancy, the company naturally moves away from PSU business.
• Specialty mix improvement: ARPOB increases because (a) within each specialty, the quantum of high-teen procedures rises, and (b) more beds are allocated to and filled by high-ARPOB specialties like Oncology and Cardiology. Beds are largely fungible except for some daycare beds.
• International patient revenue: Grew 43% YoY and 10% QoQ, now at 120% of pre-COVID levels, contributing meaningfully to ARPOB improvement. Management sees an exponential medium-term opportunity, calling India less than 5% of US costs and less than half of Thailand's.
• Annual price increase: A 2–2.5% across-the-board price increase was implemented from 1 April for in-hospital diagnostics and other services.

Abhay Soi: "I think your ARPOB is being generated by payor mix and specialty mix. It is not only purely payor mix. We have also seen a massive increase in international business, which plays on the ARPOB."

Margins & Profitability

• PAT growth of 85% YoY: Driven by improvement in operating metrics across all hospitals and lower finance costs.
• EBITDA margin vs EBITDA per bed: Reported operating margin was marginally lower QoQ (28.2% vs 28.3%), but EBITDA per bed increased. Management explicitly prioritizes EBITDA per bed over margin percentage, arguing a ₹10,000 surgery at 20% margin beats a ₹2,000 surgery at 50% margin.
• Institutional volume trend: Institutional bed share fell to 29% from 33% YoY. Management is able to retain that business and do more because of marginally more capacity and higher operating levels, but the trend is still downward. The company has paused slightly expecting some increment, but the direction remains lower.
• Digital channel margins: Digital revenue is just a booking channel; margins do not change, and customer acquisition costs and advertising are described as "meaningless here."

Abhay Soi: "I focus more on EBITDA per bed, not operating margin, because you would rather do a \$10,000 surgery and have a 20% margin than do a \$2,000 surgery and have a 50% margin, right."

Growth Strategy & Capital Deployment

• Geographic expansion criteria: Management will only enter cities where at least a few competitors have proven viability, using a cluster approach (never just one hospital in a city). A list of 21 target cities exists. Tier-II and Tier-III cities are attractive: Mohali is the highest-ROCE business, Dehradun the second-highest.
• Asset-light model: Management promised announcements "over the next couple of quarters" on an asset-light approach, particularly for greenfields, to decrease construction and development risk in geographies where the company does not yet have a presence.
• M&A pipeline: Consolidation is occurring and conversations are plentiful. The company looks for chains and clusters, not single assets, and targets a 20% ROCE three to five years out. If the CARE Hyderabad acquisition does not close, management says there are plenty of other meaningful opportunities that fit its criteria.
• Land constraints in core markets: No land is available on the main Golf Course Road in Gurgaon. No new hospital has come up in Mumbai in 20 years or in Delhi for 12 years (maybe one), because land is unavailable at viable cost. Hospitals face a 45-meter height limit and need 4–5 acres of contiguous land for a 400-bed facility.
• Stake dilution for M&A: The promoter would not shy away from dilution if a great merger or acquisition opportunity arises for the company's growth, though he will not leverage his personal stock and his salary does not permit buying more.

Abhay Soi: "We have been very clear about two things that we will only look at places where at least a few of our competitors have proven viability. We will go there and we will do it better, like we do in each one of the micro-markets that we currently operate in."

Guidance & Commitments

Key Metrics